Zai Lab Limited (ZLAB) Tuesday said the Phase 3 study of KarXT for the Treatment of Schizophrenia in China met its primary goal.
In the study, KarXT showed a statistically significant 9.2-point reduction in Positive and Negative Syndrome Scale (PANSS) total score, a measure of schizophrenia symptom severity, at Week 5 compared to placebo.
Further, no new safety signals were found compared to prior KarXT trials in schizophrenia.
Based on these results, the company plans to submit a new drug application to China's National Medical Products Administration (NMPA) in early 2025.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.